Miles To Go Before Savient Krystexxa Approval; REMS Talks Are Next Step
Executive Summary
Now that gout drug candidate Krystexxa has passed muster with FDA's Arthritis Drugs Advisory Committee, its next major hurdle is agency approval. But with only six weeks to go until its Aug. 1 user fee date and what's expected to be a fairly complex Risk Evaluation and Mitigation Strategy, odds are FDA will be unable to meet that timeline
You may also be interested in...
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
Savient's Gout Therapy Krystexxa Delayed At FDA.
Manufacturing fixes should be straightforward - but the REMS submission could be tricky.
Savient's Gout Therapy Krystexxa Delayed At FDA
The biggest delay in Savient's resubmission of its gout therapy Krystexxa (pegloticase) could come from FDA's request that the sponsor include detailed materials for its Risk Evaluation and Mitigation Strategy as part of the resubmission